#ES­MO17 roundup: Idera shares spike on ear­ly TLR9 com­bo da­ta; Ery­tech touts pan­cre­at­ic can­cer PhI­Ib da­ta

MADRID — Shares of Idera $IDRA shot up 20% in pre-mar­ket trad­ing on Mon­day as in­vestors caught up with an en­cour­ag­ing look at ear­ly-stage da­ta for its TLR9 drug IMO-2125 with Bris­tol-My­ers’ Yer­voy. Re­searchers tracked a 44% re­sponse rate — 4 of 9 pa­tients who had failed Keytru­da or Op­di­vo. There was one com­plete re­sponse in the group, who faced poor odds in fight­ing their tu­mors.

Ery­tech red blood cell ther­a­py promis­ing in PhI­Ib pan­cre­at­ic can­cer study

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.